25

BNC Korea Co. Ltd

256840 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

2,210.00KRW-40.00 (-1.78%)

Price History

Full chart

Market Stats

Previous Close2,250.00
Open2,250.00
Day Range2,205.00 – 2,325.00
52-Week Range2,050.00 – 6,083.55
Volume220.97K
Market Cap216.81B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield2.14%
Beta0.94
50-Day Avg2,629.30
200-Day Avg3,583.28

About

BNC KOREA, Inc. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia. It also provides HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration; Hibarry, a bio-absorbable gel and solution mixture used to prevent adhesion of the spinal cord post-surgery; and GentaQ a beauty face, and home and other care products under the I.st name. The company was formerly known as BNC Korea Co., Ltd. and changed its name to BNC KOREA, Inc. in April 2026. The company also exports its products to 45 countries. BNC KOREA, Inc. was incorporated in 2007 and is headquartered in Daegu, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Wan-Gyu Choi
  • Employees264
  • Headquarters#405, Structure 1, Daegu, South Korea, Korea
  • Websitehttps://www.bnckorea.co.kr

Leadership

  • Mr. Wan-Gyu ChoiChief Executive Officer · b. 1958

Financials

Income Statement

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00017.67B19.44B25.25B42.30B81.00B89.23B95.90B
Growth (%)----+10.01%+29.89%+67.55%+91.47%+10.16%+7.47%
Cost of Revenue---7.18B8.77B12.15B23.79B44.69B47.48B56.52B
Gross Profit---10.48B10.67B13.10B18.51B36.31B41.75B39.38B
Gross Margin---59.34%54.87%51.87%43.76%44.82%46.79%41.06%
Operating Expense---9.01B9.72B27.65B28.61B28.29B31.16B37.64B
Operating Income-16.77M-42.23M-39.51M1.48B947.86M-14.55B-10.10B8.01B10.59B1.73B
Operating Margin---8.35%4.88%-57.65%-23.87%9.89%11.87%1.81%
EBITDA-------38.84B26.52B25.27B16.34B
EBITDA Margin-------91.82%32.74%28.32%17.04%
Net Income-11.88M106.19M159.13M-5.40B1.42B-176.27B-44.70B25.69B13.31B2.84B
Net Income Margin----30.57%7.33%-698.13%-105.68%31.71%14.91%2.96%
R&D----1.70B8.88B5.40B4.97B2.71B5.14B
R&D as % of Total Revenue----8.72%35.15%12.76%6.13%3.04%5.36%
Interest Expense0000104.52M2.37B1.90B679.66M334.38M629.91M
Interest Expense % of Total Revenue---0.00%0.54%9.40%4.50%0.84%0.37%0.66%

Balance Sheet

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.97B14.90B15.08B49.60B67.62B134.71B232.52B236.15B267.07B277.99B
Total Liabilities1.74B1.57B1.60B22.02B30.63B84.05B48.57B26.62B30.58B38.45B
Total Equity13.22B13.33B13.49B27.58B36.99B50.66B183.95B209.53B229.87B233.70B
Cash258.06M15.56M88.77M22.40B7.43B1.04M2.11M330.00K90.80B99.24B
Total Debt1.51B1.54B1.57B12.78B24.23B-----
Net Debt----16.57B20.36B----

Cash Flow

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow186.04M-80.31M1.93B3.78B3.85B-11.27B-5.51B16.43B16.70B7.16B
Investing Cash Flow-14.70B-162.19M-256.01M7.09B-31.98B-8.56B-36.31B-43.86B-12.46B-
Financing Cash Flow14.77B1.73B1.73B1.36B13.62B44.35B123.77B-18.18B15.64B-
Capital Expenditure05.51B5.51B7.82B31.63B8.41B19.19B8.25B18.08B9.11B
Free Cash Flow-----27.91B-19.68B-24.70B8.18B-1.38B-1.95B
FCF to OCF-----724.21%174.59%448.23%49.78%-8.25%-27.19%

Earnings

Report DateMar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------------------------
EPS Actual2.662.983.165.544.594.074.737.384.825.563.58-145.6715.3812.007.88-7.94-98.20-33.38-6666.96269.71-310.01-214.00-36.90-201.70-12.2673.00122.60150.6337.304.4627.00127.7574.264.92-2.74-34.62-15.12-16.52
Surprise--------------------------------------
Timing--------------------------------------

Key Statistics & Ratios

Market Cap216.81B
Enterprise Value110.81B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.38
Price / Book0.79
Revenue (TTM)91.19B
Gross Profit (TTM)32.80B
EBITDA6.22B
Profit Margin-5.18%
Operating Margin-3.12%
Return on Equity-2.69%
Return on Assets-1.33%
Shares Outstanding68.39M
Shares Float54.95M
Beta0.94
Dividend Yield2.14%
Dividend Rate70.00
Payout Ratio166.67%

Dividends

20251×
70.00Dec 29, 2025

Stock Splits

  • Jan 25, 20221231:1136